{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:47:43Z","timestamp":1793422063685,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13045-015-0213-6","type":"journal-article","created":{"date-parts":[[2015,10,8]],"date-time":"2015-10-08T08:38:01Z","timestamp":1444293481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":159,"title":["Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab"],"prefix":"10.1186","volume":"8","author":[{"given":"Thomas","family":"K\u00f6hnke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Krupka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kn\u00f6sel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,8]]},"reference":[{"issue":"1","key":"213_CR1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-014-0058-4","volume":"7","author":"T Suresh","year":"2014","unstructured":"Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7(1):58.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"213_CR2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8(1):104.","journal-title":"J Hematol Oncol"},{"issue":"2 Pt A","key":"213_CR3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.molimm.2015.02.033","volume":"67","author":"G Zugmaier","year":"2015","unstructured":"Zugmaier G, Klinger M, Schmidt M, Subklewe M. Clinical overview of anti-CD19 BiTE(\u00ae) and ex vivo data from anti-CD33 BiTE(\u00ae) as examples for retargeting T cells in hematologic malignancies. Mol Immunol. 2015;67(2 Pt A):58\u201366.","journal-title":"Mol Immunol"},{"issue":"1","key":"213_CR4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2014;16(1):57\u201366.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"213_CR5","first-page":"5","volume":"5","author":"CA Portell","year":"2013","unstructured":"Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol. 2013;5 Suppl 1:5\u201311.","journal-title":"Clin Pharmacol"},{"issue":"26","key":"213_CR6","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1182\/blood-2012-10-460394","volume":"120","author":"R Bassan","year":"2012","unstructured":"Bassan R. Toward victory in adult ALL: blinatumomab joins in. Blood. 2012;120(26):5094\u20135.","journal-title":"Blood"},{"issue":"3","key":"213_CR7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.13397","volume":"170","author":"TA Eyre","year":"2015","unstructured":"Eyre TA, Collins GP. Immune checkpoint inhibition in lymphoid disease. Br J Haematol. 2015;170(3):291\u2013304.","journal-title":"Br J Haematol"},{"issue":"1","key":"213_CR8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-8722-6-74","volume":"6","author":"L Shi","year":"2013","unstructured":"Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6(1):74.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"213_CR9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24\u201333.","journal-title":"Trends Mol Med"},{"issue":"9","key":"213_CR10","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/bjc.2015.124","volume":"112","author":"B Homet Moreno","year":"2015","unstructured":"Homet Moreno B, Ribas A. Anti-programmed cell death protein-1\/ligand-1 therapy in different cancers. Br J Cancer. 2015;112(9):1421\u20137.","journal-title":"Br J Cancer"},{"issue":"3","key":"213_CR11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bjh.12380","volume":"162","author":"AG Ramsay","year":"2013","unstructured":"Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 2013;162(3):313\u201325.","journal-title":"Br J Haematol"},{"issue":"26","key":"213_CR12","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"213_CR13","first-page":"3005","volume":"32","author":"R Kefford","year":"2014","unstructured":"Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meet Abstr. 2014;32(15_suppl):3005. May 20.","journal-title":"ASCO Meet Abstr"},{"issue":"1","key":"213_CR14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-014-0070-8","volume":"7","author":"AD Smith","year":"2014","unstructured":"Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014;7(1):70.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"213_CR15","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","volume":"123","author":"C Krupka","year":"2014","unstructured":"Krupka C, Kufer P, Kischel R, Zugmaier G, Bogeholz J, K\u00f6hnke T, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014;123(3):356\u201365.","journal-title":"Blood"},{"key":"213_CR16","first-page":"6","volume":"26","author":"FP Madorsky Rowdo","year":"2015","unstructured":"Madorsky Rowdo FP, Baron A, Urrutia M, Mordoh J. Immunotherapy in cancer: a combat between tumors and the immune system; you win some, you lose some. Front Immunol. 2015;26:6.","journal-title":"Front Immunol"},{"issue":"127","key":"213_CR17","first-page":"127ra37","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med Am Assoc Adv Sci. 2012;4(127):127ra37\u20137.","journal-title":"Sci Transl Med Am Assoc Adv Sci"},{"key":"213_CR18","volume-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3-BiTE\u00ae antibody construct AMG 330: reversing a T-cell induced immune escape mechanism","author":"C Krupka","year":"2015","unstructured":"Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, K\u00f6hnke T, et al. Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3-BiTE\u00ae antibody construct AMG 330: reversing a T-cell induced immune escape mechanism. Leukemia: Nature Publishing Group; 2015."},{"issue":"1","key":"213_CR19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/asheducation-2001.1.221","volume":"2001","author":"OW Press","year":"2001","unstructured":"Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Immunotherapy of non-Hodgkin\u2019s lymphomas. Hematol Am Soc. 2001;2001(1):221\u201340.","journal-title":"Hematol Am Soc"},{"issue":"1","key":"213_CR20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2011.12.009","volume":"22","author":"CW Shuptrine","year":"2012","unstructured":"Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol. 2012;22(1):3\u201313.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"213_CR21","first-page":"278","volume":"12","author":"AM Scott","year":"2012","unstructured":"Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Publ Group. 2012;12(4):278\u201387.","journal-title":"Nat Publ Group"},{"issue":"3","key":"213_CR22","first-page":"222","volume":"1","author":"L Reslan","year":"2009","unstructured":"Reslan L, Dalle S, Dumontet C. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs Landes Bioscience; 2009;1(3):222\u20139.","journal-title":"MAbs Landes Bioscience;"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-015-0213-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T16:58:36Z","timestamp":1498237116000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jhoonline.org\/content\/8\/1\/111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["213"],"URL":"https:\/\/doi.org\/10.1186\/s13045-015-0213-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,8]]},"article-number":"111"}}